Silexion Therapeutics Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLXNW research report →
Companysilexion.com
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
- CEO
- Ilan Hadar
- IPO
- 2024
- Employees
- 11
- HQ
- Jerusalem, IL
Price Chart
Valuation
- Market Cap
- $10.38K
- P/E
- -0.23
- P/S
- 0.00
- P/B
- 5.88
- EV/EBITDA
- 0.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -298.03%
- ROIC
- 1448.83%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-11,912,000 · 27.56%
- EPS
- $-8.96 · -239.39%
- Op Income
- $11.63M
- FCF YoY
- -28.63%
Performance & Tape
- 52W High
- $0.03
- 52W Low
- $0.02
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- -0.29
- Avg Volume
- 65.31K
Get TickerSpark's AI analysis on SLXNW
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 26, 26 | Shirvan Mitchell | sell | 22,818 |
| Feb 20, 26 | Noy Shlomo | other | 9,091 |
| Feb 20, 26 | Noy Shlomo | other | 10,685 |
| Feb 20, 26 | Alon Ruth | other | 10,685 |
| Feb 20, 26 | Alon Ruth | other | 9,091 |
| Feb 20, 26 | Shirvan Mitchell | other | 49,726 |
| Feb 20, 26 | Horenshtein Hadar Mirit | other | 49,726 |
| Feb 20, 26 | Hadar Ilan | other | 64,350 |
| Feb 20, 26 | Abramov Dror Yosef | other | 10,685 |
| Feb 20, 26 | Abramov Dror Yosef | other | 9,091 |
Our SLXNW Coverage
We haven't published any research on SLXNW yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLXNW Report →